Better therapies through scientific excellence

Learn moreGet in Touch

About us

Trethera is a biotechnology company focused on the discovery and development of innovative small molecules with improved efficacy and safety that control DNA replication and integrity for the treatment of hematological and solid tumors.

Technology

Trethera is discovering and developing innovative small molecules that precisely control DNA replication and integrity for the treatment of malignant diseases. Our scientific expertise spans the interface between the several metabolic pathways that control the production of nucleic acids and the signal transduction pathways that allow cells to adapt to replication stress and DNA damage repair.

LEARN MORE

Products

Trethera’s lead compound, DI-87 (TRE-515), is an orally available novel Deoxycytidine Kinase inhibitor (dCKi) with nanomolar affinity. dCK has been implicated in cancer cell proliferation and survival.

LEARN MORE

Partnering

To discuss partnering opportunities that will enable access to our technology platform for identifying novel targets in the field of nucleotide metabolism, or for product co-development and combination treatment opportunities in hematological and solid tumors, please contact us.

LEARN MORE